Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Baricitinib
Baricitinib
Routinely available
SMC (1265/17)
07/05/2025
Indication
Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
2mg and 4mg film-coated tablet
Comments
Refer to pathway or local board guidelines for preferred formulation.